Effect of Aerosolised Colistin in Ventilator Associated Pneumonia

Status Completed

Clinical Trial Summary

the management of Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) gram-negative bacilli (GNB) represent a real therapeutic dilemma in intensive care unit (ICU). Colistin remains an effective agent against MDR GNB. However, because of its side effects, mainly nephrotoxicity, other modalities than the intra venous (IV) route should be tried. Several recent data emphasize the interest of inhaled route. The investigators purpose was to evaluate the effectiveness and systemic toxicity of aerosolized colistin in ventilator associated pneumonia.

Clinical Trial Description

prospective, randomized, single-blind study comparing two groups of patients treated with aerosolised (AS) colistin versus colistin intravenously (IV). Included were patients who have mechanical ventilation over 48 hours and that have developed a VAP. A VAP was defined as a CPIS (Clinical Pulmonary Infection Score) >6. Exclusion criteria were septic shock and/or bacteraemia. Included patients were divided into two randomized groups. The 1st received colistin in AS as 4 MU by nebulisation 3 times per 24 h. The 2nd received colistin in IV as a loading dose of 9 MU followed by 4.5MU two times per 24 h. Colistin was given for 14 days or until extubation. Patients were followed for 28 days. Therapeutic efficacy was assessed by a primary outcome: the cure of VAP at day 14 of therapy and defined as resolution of clinical and biological signs of infection that means a CPIS< 6 and bacteriological eradication. Secondary outcomes: duration of mechanical ventilation, ICU stay-length and mortality at day 28. Systemic toxicity was assessed by the occurrence of acute renal failure (ARF) defined as increase of plasma creatinine more than 1.5 times its base value. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02683603
Study type	Interventional
Source	Tunis University
Contact
Status	Completed
Phase	Phase 4
Start date	April 2013
Completion date	April 2015

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06370598` - Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia	Phase 1/Phase 2
Terminated	`NCT02806141` - Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates	Phase 3
Completed	`NCT01765530` - Efficacy Study of a Novel Device to Clean the Endotracheal Tube	N/A
Completed	`NCT00521677` - Comparison Between Two Methods of Oral Care on the Incidence of VAP	N/A
Completed	`NCT00529776` - Prophylaxis of Ventilator Associated Pneumonia by Continuous Lateral Rotation Therapy	N/A
Completed	`NCT03401463` - Assesment of the Endotracheal Tube Cuff Pressure Values in ICU Pateints Before and After Training Seminar	N/A
Completed	`NCT02950519` - Endotracheal Tube Cuff Pressures in Ventilated Patients	N/A
Completed	`NCT01875692` - Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?	N/A
Completed	`NCT00515034` - A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia	Phase 2
Recruiting	`NCT05117125` - Biomarkers for Ventilator-associated Pneumonia
Completed	`NCT04755972` - Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2	N/A
Terminated	`NCT02940626` - Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.	Phase 2
Completed	`NCT01577862` - Colistin and Rifampicin for MDR-Acinetobacter	Phase 3
Completed	`NCT00572559` - Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus	Phase 4
Withdrawn	`NCT04566172` - Preoperative Optimization to Improve Functional Status	N/A
Recruiting	`NCT04215692` - Lung Ultrasound-guided Fluid Therapy in Pediatric Intensive Care Unit Patients	N/A
Completed	`NCT03816956` - Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301	Phase 3
Active, not recruiting	`NCT01123681` - Intubation and Extubation Over 48 Hours Mechanical Ventilation	N/A
Recruiting	`NCT04839653` - Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria	N/A
Recruiting	`NCT03527992` - Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia	N/A